title: Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.
abstract: BACKGROUND
  Peripheral blood progenitor cells (PBPCs) are the most common stem cell source for allogeneic transplantations. Analysis of our collection data obtained with a Spectra Optia device (Terumo) for apheresis demonstrated collection efficacies (CEs) exceeding our internal target levels of 5 × 10(6) CD34+ cells/kg body weight of the recipient when collected on Day 5. We thus aimed to investigate whether collection on Day 4 would lead to adequate amounts of PBPCs while minimizing granulocyte-colony-stimulating factor (G-CSF) exposure in healthy donors.
  
  
  METHODS
  We compared feasibility and effectiveness of Day 5 versus Day 4 collections with data obtained from 23 and 18 allogeneic procedures, respectively.
  
  
  RESULTS
  Both groups were comparable with regard to donor and collection characteristics. Product characteristics as well as platelet loss, CE, throughput, and collection rate did not differ between both protocols. A higher contamination with white blood cells (WBCs; ×10(9) /L) was observed in products collected on Day 5 compared to Day 4 (231 [range, 181-299] vs. 203 [range, 165-239]; p = 0.004). A second apheresis procedure was required in three of 23 patients and three of 18 patients, respectively (p = 0.6) to obtain the required PBPC dose.
  
  
  CONCLUSIONS
  PBPC apheresis on Day 4 seems as feasible and effective as collection on Day 5. Collection on Day 4 produces lower WBC content in the product and allows a reduction in G-CSF exposure to healthy donors.
authors: Center for Transfusion Medicine and Hemotherapy.
authors: Sabine
authors: S
authors: Flommersfeld
authors: Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg Campus, Marburg, Germany.
authors: Kristina
authors: K
authors: Sohlbach
authors: Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg Campus, Marburg, Germany.
authors: Gabriele
authors: G
authors: Jaques
authors: Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
authors: Gregor
authors: G
authors: Bein
authors: Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg Campus, Marburg, Germany.
authors: Jörg
authors: J
authors: Hoffmann
authors: Department of Hematology, Oncology, and Immunology, University Hospital Giessen and Marburg, Marburg Campus, Marburg, Germany.
authors: Philippe
authors: P
authors: Kostrewa
authors: Center for Transfusion Medicine and Hemotherapy.|Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany.
authors: Ulrich J
authors: UJ
authors: Sachs
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D001772:Blood Cell Count; D001781:Blood Component Removal / Q000379:methods*; D001782:Blood Donors; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D013997:Time Factors
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim